Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Thrombosis Journal
Published in: Thrombosis Journal 1/2020

Open Access 01-12-2020 | COVID-19 | Review

Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory

Authors: M. Hardy, T. Lecompte, J. Douxfils, S. Lessire, J. M. Dogné, B. Chatelain, S. Testa, I. Gouin-Thibault, Y. Gruel, R. L. Medcalf, H. ten Cate, G. Lippi, F. Mullier

Published in: Thrombosis Journal | Issue 1/2020

Login to get access

Abstract

Coronavirus disease 2019 (COVID-19) is associated with extreme inflammatory response, disordered hemostasis and high thrombotic risk. A high incidence of thromboembolic events has been reported despite thromboprophylaxis, raising the question of a more effective anticoagulation. First-line hemostasis tests such as activated partial thromboplastin time, prothrombin time, fibrinogen and D-dimers are proposed for assessing thrombotic risk and monitoring hemostasis, but are vulnerable to many drawbacks affecting their reliability and clinical relevance. Specialized hemostasis-related tests (soluble fibrin complexes, tests assessing fibrinolytic capacity, viscoelastic tests, thrombin generation) may have an interest to assess the thrombotic risk associated with COVID-19. Another challenge for the hemostasis laboratory is the monitoring of heparin treatment, especially unfractionated heparin in the setting of an extreme inflammatory response. This review aimed at evaluating the role of hemostasis tests in the management of COVID-19 and discussing their main limitations.
Literature
1.
2.
Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18(6):1421–4.PubMedCrossRef
3.
Zeng F, Huang Y, Guo Y, Yin M, Chen X, Xiao L, et al. Association of inflammatory markers with the severity of COVID-19: a meta-analysis. Int J Infect Dis. 2020;96:467–74.PubMedPubMedCentralCrossRef
4.
Iba T, Levy JH. Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis. J Thromb Haemost. 2018;16(2):231–41.PubMedCrossRef
5.
Levi M, Poll T. Coagulation in patients with severe sepsis. Semin Thromb Hemost. 2015;41(1):9–15.PubMedCrossRef
6.
Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094–9.PubMedCrossRef
7.
Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–7.PubMedPubMedCentralCrossRef
8.
9.
Thomas WVJ, Johnston A, Symington E, Robinson M, Sheares K, Lavinio A, Bessera M. Thrombotic complications of patients admitted to intensive care with COVID-19 at a teaching hospital in the United Kingdom. Thromb Res. 2020;191:76–7.PubMedPubMedCentralCrossRef
10.
Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089–98.PubMedCrossRefPubMedCentral
11.
12.
Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res. 2020;191:148–50.PubMedPubMedCentralCrossRef
13.
Beun R, Kusadasi N, Sikma M, Westerink J, Huisman A. Thromboembolic events and apparent heparin resistance in patients infected with SARS-CoV-2. Int J Lab Hematol. 2020;42(Suppl 1):19–20.PubMedCrossRefPubMedCentral
14.
Artifoni M, Danic G, Gautier G, Gicquel P, Boutoille D, Raffi F, et al. Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors. J Thromb Thrombolysis. 2020;50(1):211–6.PubMedCrossRefPubMedCentral
15.
Susen S, Tacquard CA, Godon A, Mansour A, Garrigue D, Nguyen P, et al. Prevention of thrombotic risk in hospitalized patients with COVID19 and hemostasis monitoring: proposals from the French working group on perioperative Haemostasis (GIHP) the French Sdy group on thrombosis and Haemostasis (GFHT), in collaboration with the French Society for Anaesthesia and Intensive Care (SFAR). Crit Care. 2020;24(1):364.PubMedPubMedCentralCrossRef
16.
Casini A, Alberio L, Angelillo-Scherrer A, Fontana P, Gerber B, Graf L, et al. Thromboprophylaxis and laboratory monitoring for in-hospital patients with COVID-19 - a Swiss consensus statement by the working party hemostasis. Swiss Med Wkly. 2020;150:w20247.PubMed
17.
18.
Oudkerk M, Buller HR, Kuijpers D, van Es N, Oudkerk SF, McLoud TC, et al. Diagnosis, prevention, and treatment of thromboembolic complications in COVID-19: report of the National Institute for public health of the Netherlands. Radiology. 2020;201629.
19.
Zhai Z, Li C, Chen Y, Gerotziafas G, Zhang Z, Wan J, et al. Prevention and treatment of venous thromboembolism associated with coronavirus disease 2019 infection: a consensus statement before guidelines. Thromb Haemost. 2020;120(6):937–48.PubMedPubMedCentralCrossRef
20.
Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023–6.CrossRefPubMed
21.
22.
Marietta M, Ageno W, Artoni A, De Candia E, Gresele P, Marchetti M, et al. COVID-19 and haemostasis: a position paper from Italian society on thrombosis and Haemostasis (SISET). Blood Transfus. 2020;18(3):167–9.PubMedPubMedCentral
23.
24.
Frantzeskaki F, Armaganidis A, Orfanos SE. Immunothrombosis in acute respiratory distress syndrome: Cross talks between inflammation and coagulation. Respiration. 2017;93(3):212–25.PubMedCrossRef
25.
Schultz MJ, Haitsma JJ, Zhang H, Slutsky AS. Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia - a review. Crit Care Med. 2006;34(3):871–7.PubMedCrossRef
26.
Kowalewski M, Fina D, Slomka A, Raffa GM, Martucci G, Lo Coco V, et al. COVID-19 and ECMO: the interplay between coagulation and inflammation-a narrative review. Crit Care. 2020;24(1):205.PubMedPubMedCentralCrossRef
27.
28.
Voss R, Matthias FR, Borkowski G, Reitz D. Activation and inhibition of fibrinolysis in septic patients in an internal intensive care unit. Br J Haematol. 1990;75(1):99–105.PubMedCrossRef
29.
Prabhakaran P, Ware LB, White KE, Cross MT, Matthay MA, Olman MA. Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2003;285(1):L20–8.PubMedCrossRef
30.
Masi P, Hékimian G, Lejeune M, Chommeloux J, Desnos C, Pineton De Chambrun M, et al. Systemic Inflammatory Response Syndrome is a Major Contributor to COVID-19-Associated Coagulopathy: Insights from a Prospective SingleCenter Cohort Study. Circulation. 2020. Online ahead of print. https://​doi.​org/​10.​1161/​CIRCULATIONAHA.​120.​048925.
31.
Fujimoto H, Gabazza EC, Hataji O, Yuda H, D'Alessandro-Gabazza CN, Nakano M, et al. Thrombin-activatable fibrinolysis inhibitor and protein C inhibitor in interstitial lung disease. Am J Respir Crit Care Med. 2003;167(12):1687–94.PubMedCrossRef
32.
Whyte CS, Morrow GB, Mitchell JL, Chowdary P, Mutch NJ. Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19. J Thromb Haemost. 2020;18(7):1548–55.PubMedCrossRef
33.
Marchandot B, Sattler L, Jesel L, Matsushita K, Schini-Kerth V, Grunebaum L, et al. COVID-19 related coagulopathy: a distinct entity? J Clin Med. 2020;9(6):E1651.PubMedCrossRef
34.
Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417–8.PubMedPubMedCentralCrossRef
35.
36.
Huisman A, Beun R, Sikma M, Westerink J, Kusadasi N. Involvement of ADAMTS13 and von Willebrand factor in thromboembolic events in patients infected with SARS-CoV-2. Int J Lab Hematol. 2020. Online ahead of print. https://​doi.​org/​10.​1111/​ijlh.​13244.
37.
38.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62.PubMedPubMedCentralCrossRef
39.
40.
41.
42.
43.
44.
45.
Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. 2020;75(23):2950–73.PubMedCrossRefPubMedCentral
46.
47.
Longstaff C, Adcock D, Olson JD, Jennings I, Kitchen S, Mutch N, et al. Harmonisation of D-dimer - a call for action. Thromb Res. 2016;137:219–20.PubMedCrossRef
48.
Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091.PubMedPubMedCentralCrossRef
49.
Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–7.PubMedPubMedCentralCrossRef
50.
Liu Y, Sun W, Guo Y, Chen L, Zhang L, Zhao S, et al. Association between platelet parameters and mortality in coronavirus disease 2019: Retrospect Cohort Stud. Platelets. 2020: 1–7.
51.
Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta. 2020;506:145–8.PubMedPubMedCentralCrossRef
52.
Page MJ, Pretorius E. A champion of host defense: a generic large-scale cause for platelet dysfunction and depletion in infection. Semin Thromb Hemost. 2020;46(3):302–19.PubMedPubMedCentralCrossRef
53.
Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Scientific subcommittee on disseminated intravascular coagulation of the international society on T, et al. towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86(5):1327–30.PubMedCrossRef
54.
Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol. 2009;145(1):24–33.PubMedCrossRef
55.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13.PubMedPubMedCentralCrossRef
56.
Refaai MA, Riley P, Mardovina T, Bell PD. The clinical significance of fibrin monomers. Thromb Haemost. 2018;118(11):1856–66.PubMedCrossRef
57.
Wada H, Takahashi H, Uchiyama T, Eguchi Y, Okamoto K, Kawasugi K, et al. The approval of revised diagnostic criteria for DIC from the Japanese society on thrombosis and hemostasis. Thromb J. 2017;15:17.PubMedPubMedCentralCrossRef
58.
Asakura H, Takahashi H, Uchiyama T, Eguchi Y, Okamoto K, Kawasugi K, et al. Proposal for new diagnostic criteria for DIC from the Japanese society on thrombosis and hemostasis. Thromb J. 2016;14:42.PubMedPubMedCentralCrossRef
59.
Brionne-François M, Geara C, Riviere M, Gautier P, Davy JB, Le Querrec A, et al. Etude prospective de l’utilisation des monomères de fibrine dans le calcul du score diagnostic de CIVD de l’ISTH (Poster). 33e congrès de la Société Française d'Hématologie (SFH); Paris. 2016.
60.
Westerlund E, Woodhams BJ, Eintrei J, Soderblom L, Antovic JP. The evaluation of two automated soluble fibrin assays for use in the routine hospital laboratory. Int J Lab Hematol. 2013;35(6):666–71.PubMedCrossRef
61.
Hamano A, Tanaka S, Takeda Y, Umeda M, Sakata Y. A novel monoclonal antibody to fibrin monomer and soluble fibrin for the detection of soluble fibrin in plasma. Clin Chim Acta. 2002;318(1–2):25–32.PubMedCrossRef
62.
Dempfle CE. The use of soluble fibrin in evaluating the acute and chronic hypercoagulable state. Thromb Haemost. 1999;82(2):673–83.PubMed
63.
Lutze G, Naumann C. Useful Facts about Coagulation: Questions/answers ; [general Principles, Clinical Aspects/treatment, Preanalytical/analytical Aspects]: Roche Diagnostics; 2004.
64.
Madoiwa S, Kitajima I, Ohmori T, Sakata Y, Mimuro J. Distinct reactivity of the commercially available monoclonal antibodies of D-dimer and plasma FDP testing to the molecular variants of fibrin degradation products. Thromb Res. 2013;132(4):457–64.PubMedCrossRef
65.
Lippi G, Cervellin G, Franchini M, Favaloro EJ. Biochemical markers for the diagnosis of venous thromboembolism: the past, present and future. J Thromb Thrombolysis. 2010;30(4):459–71.PubMedCrossRef
66.
Favaloro EJ, Thachil J. Reporting of D-dimer data in COVID-19: some confusion and potential for misinformation. Clin Chem Lab Med. 2020;58(8):1191–9.PubMedCrossRef
67.
Hatada T, Wada H, Kawasugi K, Okamoto K, Uchiyama T, Kushimoto S, et al. Analysis of the cutoff values in fibrin-related markers for the diagnosis of overt DIC. Clin Appl Thromb Hemost. 2012;18(5):495–500.PubMedCrossRef
68.
Olson JD, Cunningham MT, Higgins RA, Eby CS, Brandt JT. D-dimer: simple test, tough problems. Arch Pathol Lab Med. 2013;137(8):1030–8.PubMedCrossRef
69.
Suzuki K, Wada H, Imai H, Iba T, Thachil J, Toh CH, et al. A re-evaluation of the D-dimer cut-off value for making a diagnosis according to the ISTH overt-DIC diagnostic criteria: communication from the SSC of the ISTH. J Thromb Haemost. 2018;16(7):1442–4.PubMedCrossRef
70.
Favresse J, Lippi G, Roy PM, Chatelain B, Jacqmin H, Ten Cate H, et al. D-dimer: Preanalytical, analytical, postanalytical variables, and clinical applications. Crit Rev Clin Lab Sci. 2018;55(8):548–77.PubMedCrossRef
71.
72.
Pieters M, Philippou H, Undas A, de Lange Z, Rijken DC, Mutch NJ, et al. An international study on the feasibility of a standardized combined plasma clot turbidity and lysis assay: communication from the SSC of the ISTH. J Thromb Haemost. 2018;16(5):1007–12.PubMedCrossRef
73.
Glassman A, Abram M, Baxter G, Swett A. Euglobulin lysis times: an update. Ann Clin Lab Sci. 1993;23(5):329–32.PubMed
74.
Cohen W, Alessi MC. Temps de lyse. EMC Biologie médicale. 2012;7(3):1–3.
75.
Scheer FA, Shea SA. Human circadian system causes a morning peak in prothrombotic plasminogen activator inhibitor-1 (PAI-1) independent of the sleep/wake cycle. Blood. 2014;123(4):590–3.PubMedPubMedCentralCrossRef
76.
Budkowska M, Lebiecka A, Marcinowska Z, Wozniak J, Jastrzebska M, Dolegowska B. The circadian rhythm of selected parameters of the hemostasis system in healthy people. Thromb Res. 2019;182:79–88.PubMedCrossRef
77.
Eriksson E, Tengborn L, Risberg B. The effect of various anticoagulant/antiplatelet mixtures on determination of plasminogen activator inhibitor, platelet proteins and hemostasis parameters. Thromb Haemost. 1989;61(3):511–6.PubMedCrossRef
78.
Paramo JA, de Boer A, Colucci M, Jonker JJ, Collen D. Plasminogen activator inhibitor (PA-inhibitor) activity in the blood of patients with deep vein thrombosis. Thromb Haemost. 1985;54(3):725.PubMedCrossRef
79.
Juhan-Vague I, Alessi MC, Fossat C, Declerck PJ, Kruithof EK. Plasma determination of plasminogen activator inhibitor 1 antigen must be performed in blood collected on antiplatelet/anticoagulant mixture. Thromb Haemost. 1987;58(4):1096.PubMedCrossRef
80.
Mertens JC, Claesen K, Leenaerts D, Sim Y, Lambeir AM, Hendriks D. Inhibition of the procarboxypeptidase U (proCPU, TAFI, proCPB2) system due to hemolysis. J Thromb Haemost. 2019;17(6):878–84.PubMedCrossRef
81.
Amiral J, Seghatchian J. The contact system at the crossroads of various key patho- physiological functions: update on present understanding, laboratory exploration and future perspectives. Transfus Apher Sci. 2019;58(2):216–22.PubMedCrossRef
82.
Scarlatescu E, Juffermans NP, Thachil J. The current status of viscoelastic testing in septic coagulopathy. Thromb Res. 2019;183:146–52.PubMedCrossRef
83.
Cointe S, Harti Souab K, Bouriche T, Vallier L, Bonifay A, Judicone C, et al. A new assay to evaluate microvesicle plasmin generation capacity: validation in disease with fibrinolysis imbalance. J Extracell Vesicles. 2018;7(1):1494482.PubMedPubMedCentralCrossRef
84.
Vallier L, Cointe S, Lacroix R, Bonifay A, Judicone C, Dignat-George F, et al. Microparticles and fibrinolysis. Semin Thromb Hemost. 2017;43(2):129–34.PubMedCrossRef
85.
Harahsheh Y, Duff OC, Ho KM. Thromboelastography predicts thromboembolism in critically ill Coagulopathic patients. Crit Care Med. 2019;47(6):826–32.PubMedCrossRef
86.
McCrath DJ, Cerboni E, Frumento RJ, Hirsh AL, Bennett-Guerrero E. Thromboelastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction. Anesth Analg. 2005;100(6):1576–83.PubMedCrossRef
87.
Gary JL, Schneider PS, Galpin M, Radwan Z, Munz JW, Achor TS, et al. Can Thrombelastography predict venous thromboembolic events in patients with severe extremity trauma? J Orthop Trauma. 2016;30(6):294–8.PubMed
88.
Cotton BA, Minei KM, Radwan ZA, Matijevic N, Pivalizza E, Podbielski J, et al. Admission rapid thrombelastography predicts development of pulmonary embolism in trauma patients. J Trauma Acute Care Surg. 2012;72(6):1470–5.PubMedCrossRef
89.
Brill JB, Badiee J, Zander AL, Wallace JD, Lewis PR, Sise MJ, et al. The rate of deep vein thrombosis doubles in trauma patients with hypercoagulable thromboelastography. J Trauma Acute Care Surg. 2017;83(3):413–9.PubMedCrossRef
90.
Coleman JR, Kay AB, Moore EE, Moore HB, Gonzalez E, Majercik S, et al. It’s sooner than you think: blunt solid organ injury patients are already Hypercoagulable upon hospital admission - results of a bi-institutional, prospective study. Am J Surg. 2019;218(6):1065–73.PubMedCrossRefPubMedCentral
91.
Dai Y, Lee A, Critchley LA, White PF. Does thromboelastography predict postoperative thromboembolic events? A systematic review of the literature. Anesth Analg. 2009;108(3):734–42.PubMedCrossRef
92.
Pavoni V, Gianesello L, Pazzi M, Stera C, Meconi T, Frigieri FC. Evaluation of coagulation function by rotation thromboelastometry in critically ill patients with severe COVID-19 pneumonia. J Thromb Thrombolysis. 2020. Online ahead of print. https://​doi.​org/​10.​1007/​s11239-020-02130-7.
93.
Ranucci M, Ballotta A, Di Dedda U, Bayshnikova E, Dei Poli M, Resta M, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost. 2020;18(7):1747–51.PubMedCrossRef
94.
Spiezia L, Boscolo A, Poletto F, Cerruti L, Tiberio I, Campello E, et al. COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. Thromb Haemost. 2020;120(6):998–1000.PubMedPubMedCentralCrossRef
95.
96.
Raza I, Davenport R, Rourke C, Platton S, Manson J, Spoors C, et al. The incidence and magnitude of fibrinolytic activation in trauma patients. J Thromb Haemost. 2013;11(2):307–14.PubMedCrossRef
97.
98.
Ranucci M, Di Dedda U, Baryshnikova E. Trials and tribulations of viscoelastic-based determination of Fibrinogen concentration. Anesth Analg. 2020;130(3):644–53.PubMedCrossRef
99.
Chitlur M, Sorensen B, Rivard GE, Young G, Ingerslev J, Othman M, et al. Standardization of thromboelastography: a report from the TEG-ROTEM working group. Haemophilia. 2011;17(3):532–7.PubMedCrossRef
100.
Camenzind V, Bombeli T, Seifert B, Jamnicki M, Popovic D, Pasch T, et al. Citrate storage affects Thrombelastograph analysis. Anesthesiology. 2000;92(5):1242–9.PubMedCrossRef
101.
Zambruni A, Thalheimer U, Leandro G, Perry D, Burroughs AK. Thromboelastography with citrated blood: comparability with native blood, stability of citrate storage and effect of repeated sampling. Blood Coagul Fibrinolysis. 2004;15(1):103–7.PubMedCrossRef
102.
Wasowicz M, Srinivas C, Meineri M, Banks B, McCluskey SA, Karkouti K. Technical report: analysis of citrated blood with thromboelastography: comparison with fresh blood samples. Can J Anaesth. 2008;55(5):284–9.PubMedCrossRef
103.
Gilman EA, Koch CD, Santrach PJ, Schears GJ, Karon BS. Fresh and citrated whole-blood specimens can produce different thromboelastography results in patients on extracorporeal membrane oxygenation. Am J Clin Pathol. 2013;140(2):165–9.PubMedCrossRef
104.
Haas T, Spielmann N, Cushing M. Impact of incorrect filling of citrate blood sampling tubes on thromboelastometry. Scand J Clin Lab Invest. 2015;75(8):717–9.PubMed
105.
Tang N, Jin X, Sun Z, Jian C. Effects of hemolysis and lipemia interference on kaolin-activated thromboelastography, and comparison with conventional coagulation tests. Scand J Clin Lab Invest. 2017;77(2):98–103.PubMedCrossRef
106.
Spiezia L, Radu C, Marchioro P, Bertini D, Rossetto V, Castelli M, et al. Peculiar whole blood rotation thromboelastometry (Rotem) profile in 40 sideropenic anaemia patients. Thromb Haemost. 2008;100(6):1106–10.PubMedCrossRef
107.
Ogawa S, Szlam F, Bolliger D, Nishimura T, Chen EP, Tanaka KA. The impact of hematocrit on fibrin clot formation assessed by rotational thromboelastometry. Anesth Analg. 2012;115(1):16–21.PubMedCrossRef
108.
Solomon C, Rahe-Meyer N, Schochl H, Ranucci M, Gorlinger K. Effect of haematocrit on fibrin-based clot firmness in the FIBTEM test. Blood Transfus. 2013;11(3):412–8.PubMedPubMedCentral
109.
Glas M, Mauer D, Kassas H, Volk T, Kreuer S. Sample transport by pneumatic tube system alters results of multiple electrode aggregometry but not rotational thromboelastometry. Platelets. 2013;24(6):454–61.PubMedCrossRef
110.
Amann G, Zehntner C, Marti F, Colucci G. Effect of acceleration forces during transport through a pneumatic tube system on ROTEM(R) analysis. Clin Chem Lab Med. 2012;50(8):1335–42.PubMedCrossRef
111.
Le Quellec S, Paris M, Nougier C, Sobas F, Rugeri L, Girard S, et al. Pre-analytical effects of pneumatic tube system transport on routine haematology and coagulation tests, global coagulation assays and platelet function assays. Thromb Res. 2017;153:7–13.PubMedCrossRef
112.
Nissen PH, Wulff DE, Torring N, Hvas AM. The impact of pneumatic tube transport on whole blood coagulation and platelet function assays. Platelets. 2018;29(4):421–4.PubMedCrossRef
113.
Kintigh J, Monagle P, Ignjatovic V. A review of commercially available thrombin generation assays. Res Pract Thromb Haemost. 2018;2(1):42–8.PubMedCrossRef
114.
Douxfils J, Morimont L, Bouvy C, de Saint-Hubert M, Devalet B, Devroye C, et al. Assessment of the analytical performances and sample stability on ST Genesia system using the STG-DrugScreen application. J Thromb Haemost. 2019;17(8):1273–87.PubMedPubMedCentralCrossRef
115.
Carlo A, Arnaud E, Woodhams BJ. The use of polybrene for heparin neutralization in the thrombin generation test. Boston: Poster presented at: XXII ISTH Congress & 55th Annual SSC Meeting; 2009.
116.
Loeffen R, Kleinegris MC, Loubele ST, Pluijmen PH, Fens D, van Oerle R, et al. Preanalytic variables of thrombin generation: towards a standard procedure and validation of the method. J Thromb Haemost. 2012;10(12):2544–54.PubMedCrossRef
117.
Alhazzani W, Lim W, Jaeschke RZ, Murad MH, Cade J, Cook DJ. Heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review and meta-analysis of randomized trials. Crit Care Med. 2013;41(9):2088–98.PubMedCrossRef
118.
Lim W, Meade M, Lauzier F, Zarychanski R, Mehta S, Lamontagne F, et al. Failure of anticoagulant thromboprophylaxis: risk factors in medical-surgical critically ill patients*. Crit Care Med. 2015;43(2):401–10.PubMedCrossRef
119.
Testa S, Prandoni P, Paoletti O, Morandini R, Tala M, Dellanoce C, et al. Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: the Cremona experience. J Thromb Haemost. 2020;18(6):1320–3.PubMedCrossRef
120.
121.
Wakefield TW, Greenfield LJ, Rolfe MW, DeLucia A 3rd, Strieter RM, Abrams GD, et al. Inflammatory and procoagulant mediator interactions in an experimental baboon model of venous thrombosis. Thromb Haemost. 1993;69(2):164–72.PubMedCrossRef
122.
Tichelaar YI, Kluin-Nelemans HJ, Meijer K. Infections and inflammatory diseases as risk factors for venous thrombosis. A systematic review. Thromb Haemost. 2012;107(5):827–37.PubMedCrossRef
123.
Vicenzi E, Canducci F, Pinna D, Mancini N, Carletti S, Lazzarin A, et al. Coronaviridae and SARS-associated coronavirus strain HSR1. Emerg Infect Dis. 2004;10(3):413–8.PubMedPubMedCentralCrossRef
124.
Bounameaux H, de Moerloose P. Is laboratory monitoring of low-molecular-weight heparin therapy necessary? No J Thromb Haemost. 2004;2(4):551–4.PubMedCrossRef
125.
Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e24S–43S.PubMedPubMedCentralCrossRef
126.
Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med. 2000;160(2):181–8.PubMedCrossRef
127.
Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005;106(8):2710–5.PubMedCrossRef
128.
Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med. 1972;287(7):324–7.PubMedCrossRef
129.
Gouin-Thibaut I, Martin-Toutain I, Peynaud-Debayle E, Marion S, Napol P, Alhenc-Gelas M, et al. Monitoring unfractionated heparin with APTT: a French collaborative study comparing sensitivity to heparin of 15 APTT reagents. Thromb Res. 2012;129(5):666–7.PubMedCrossRef
130.
Cuker A, Raby A, Moffat KA, Flynn G, Crowther MA. Interlaboratory variation in heparin monitoring: lessons from the quality management program of Ontario coagulation surveys. Thromb Haemost. 2010;104(4):837–44.PubMed
131.
Marlar RA, Clement B, Gausman J. Activated partial Thromboplastin time monitoring of unfractionated heparin therapy: issues and recommendations. Semin Thromb Hemost. 2017;43(3):253–60.PubMed
132.
Bain B, Forster T, Sleigh B. Heparin and the activated partial thromboplastin time--a difference between the in-vitro and in-vivo effects and implications for the therapeutic range. Am J Clin Pathol. 1980;74(5):668–73.PubMedCrossRef
133.
Gouin-Thibault I LT, Sie P, Siguret V. Anticoagulants usuels : maniement et gestion des complications. In: Encyclopédie Médico-Chirurgicale Akos (traité de Médecine) 2013.
134.
Levine SP, Sorenson RR, Harris MA, Knieriem LK. The effect of platelet factor 4 (PF4) on assays of plasma heparin. Br J Haematol. 1984;57(4):585–96.PubMedCrossRef
135.
Mischke R, Wolling H. Influence of fibrinogen degradation products on thrombin time, activated partial thromboplastin time and prothrombin time of canine plasma. Haemostasis. 2000;30(3):123–30.PubMed
136.
Vandiver JW, Vondracek TG. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin. Pharmacotherapy. 2012;32(6):546–58.PubMedCrossRef
137.
Erdem-Eraslan L, Hens JJH, van Rossum AP, Frasa MAM, Keuren JFW. Inter-individual variability in phospholipid-dependent interference of C-reactive protein on activated partial thromboplastin time. Br J Haematol. 2018;183(4):681–3.PubMedCrossRef
138.
Devreese KM, Verfaillie CJ, De Bisschop F, Delanghe JR. Interference of C-reactive protein with clotting times. Clin Chem Lab Med 2015; 53(5): e141–5.
139.
Uthman IW, Gharavi AE. Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum. 2002;31(4):256–63.PubMedCrossRef
140.
141.
142.
Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and Antiphospholipid antibodies in patients with Covid-19. N Engl J Med. 2020;382(17):e38.PubMedCrossRef
143.
144.
Sangle NA, Rodgers GM, Smock KJ. Prevalence of heparin in samples submitted for lupus anticoagulant testing. Lab Hematol. 2011;17(1):6–11.PubMedCrossRef
145.
De Kesel PMM, Devreese KMJ. The effect of unfractionated heparin, enoxaparin, and danaparoid on lupus anticoagulant testing: can activated carbon eliminate false-positive results? Res Pract Thromb Haemost. 2020;4(1):161–8.PubMedCrossRef
146.
Favresse J, Lardinois B, Sabor L, Devalet B, Vandepapeliere J, Braibant M, et al. Evaluation of the DOAC-stop(R) procedure to overcome the effect of DOACs on several thrombophilia screening tests. TH Open. 2018;2(2):e202–e9.PubMedPubMedCentralCrossRef
147.
Toh CH, Samis J, Downey C, Walker J, Becker L, Brufatto N, et al. Biphasic transmittance waveform in the APTT coagulation assay is due to the formation of a Ca(++)-dependent complex of C-reactive protein with very-low-density lipoprotein and is a novel marker of impending disseminated intravascular coagulation. Blood. 2002;100(7):2522–9.PubMedCrossRef
148.
Sevenet PO, Depasse F. Clot waveform analysis: where do we stand in 2017? Int J Lab Hematol. 2017;39(6):561–8.PubMedCrossRef
149.
Hemker HC, Béguin S. The activity of heparin in the presence and absence of Ca2+ ions; why the anti-Xa activity of LMW heparins is about two times overestimated. Thromb Haemost. 1993;70(04):717–8.PubMedCrossRef
150.
Kostousov V, Nguyen K, Hundalani SG, Teruya J. The influence of free hemoglobin and bilirubin on heparin monitoring by activated partial thromboplastin time and anti-Xa assay. Arch Pathol Lab Med. 2014;138(11):1503–6.PubMedCrossRef
151.
152.
153.
Depasse F, Gilbert M, Goret V, Rolland N, Samama MM. Anti-Xa monitoring: inter-assay variability. Thromb Haemost. 2000;84(6):1122–3.PubMed
154.
Uprichard J, Manning RA, Laffan MA. Monitoring heparin anticoagulation in the acute phase response. Br J Haematol. 2010;149(4):613–9.PubMedCrossRef
155.
156.
157.
Eikelboom JW, Hirsh J. Monitoring unfractionated heparin with the aPTT: time for a fresh look. Thromb Haemost. 2006;96(5):547–52.PubMed
158.
Guermazi S, Znazen R. Resistance to curative treatment by unfractionned heparin. Rev Med Interne. 2009;30(4):331–4.PubMedCrossRef
159.
Marchetti M, Barelli S, Zermatten MG, Monnin-Respen F, Matthey-Guirao E, Nicolas N, et al. Rapid and accurate Bayesian diagnosis of heparin-induced thrombocytopenia. Blood. 2020;135(14):1171–84.PubMed
160.
161.
Young E, Podor TJ, Venner T, Hirsh J. Induction of the acute-phase reaction increases heparin-binding proteins in plasma. Arterioscler Thromb Vasc Biol. 1997;17(8):1568–74.PubMedCrossRef
162.
Young E, Venner T, Ribau J, Shaughnessy S, Hirsh J, Podor TJ. The binding of unfractionated heparin and low molecular weight heparin to thrombin-activated human endothelial cells. Thromb Res. 1999;96(5):373–81.PubMedCrossRef
163.
Finley A, Greenberg C. Review article: heparin sensitivity and resistance: management during cardiopulmonary bypass. Anesth Analg. 2013;116(6):1210–22.PubMedCrossRef
164.
Levine MN, Hirsh J, Gent M, Turpie AG, Cruickshank M, Weitz J, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med. 1994;154(1):49–56.PubMedCrossRef
165.
Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126(3 Suppl):188S–203S.PubMedCrossRef
166.
Gruel Y, De Maistre E, Pouplard C, Mullier F, Susen S, Roullet S, et al. Diagnosis and management of heparin-induced thrombocytopenia. Anaesth Crit Care Pain Med. 2020;39(2):291–310.PubMedCrossRef
167.
Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood. 2012;120(20):4160–7.PubMedPubMedCentralCrossRef
168.
Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4(4):759–65.PubMedCrossRef
169.
Crowther M, Cook D, Guyatt G, Zytaruk N, McDonald E, Williamson D, et al. Heparin-induced thrombocytopenia in the critically ill: interpreting the 4Ts test in a randomized trial. J Crit Care. 2014;29(3):470 e7–15.PubMedCrossRef
170.
Linkins LA, Bates SM, Lee AY, Heddle NM, Wang G, Warkentin TE. Combination of 4Ts score and PF4/H-PaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study. Blood. 2015;126(5):597–603.PubMedCrossRef
171.
172.
173.
Metadata
Title
Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory
Authors
M. Hardy
T. Lecompte
J. Douxfils
S. Lessire
J. M. Dogné
B. Chatelain
S. Testa
I. Gouin-Thibault
Y. Gruel
R. L. Medcalf
H. ten Cate
G. Lippi
F. Mullier
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Thrombosis Journal / Issue 1/2020
Electronic ISSN: 1477-9560
DOI
https://doi.org/10.1186/s12959-020-00230-1

Other articles of this Issue 1/2020

Thrombosis Journal 1/2020 Go to the issue

Research

Analysis of the association between resolution of disseminated intravascular coagulation (DIC) and treatment outcomes in post-marketing surveillance of thrombomodulin alpha for DIC with infectious disease and with hematological malignancy by organ failure

Research

Maternal mortality following thromboembolism; incidences and prophylaxis strategies

Research

Increased dose primary thromboprophylaxis in ambulatory patients with advanced pancreatic ductal adenocarcinoma, a single centre cohort study

Review

Factor V Leiden 1691G > A mutation and the risk of recurrent pregnancy loss (RPL): systematic review and meta-analysis

Research

Effects of concomitant use of prasugrel with edoxaban on bleeding time, pharmacodynamics, and pharmacokinetics of edoxaban in healthy elderly Japanese male subjects: a clinical pharmacology study

Review

Disseminated intravascular coagulation: new identity as endotheliopathy-associated vascular microthrombotic disease based on in vivo hemostasis and endothelial molecular pathogenesis
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits